Article

Topical NSAID dosed b.i.d. effectively treats macular edema following cataract surgery

Fort Lauderdale, FL-The new b.i.d. dosed topical non-steroidal anti-inflammatory drug (NSAID) bromfenac ophthalmic solution 0.09% (Xibrom, Ista Pharmaceuticals), was found to be as effective as either diclofenac sodium 0.1% ophthalmic solution (Voltaren, Novartis Ophthalmics) or ketorolac tromethamine 0.5% (Acular, Allergan) ophthalmic solution dosed q.i.d. in a recent study of acute pseudophakic cystoid macular edema (CME) treatment following uncomplicated cataract surgery.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.